Bacteremia and SepsisNCT00932243
Bacteremia in Intensive Care Unit (ICU)
An observational study of Bacteremia and Sepsis and Toll-Like-Receptors (TLRs), run by University of Thessaly at 1 site in Greece.
Trial summary
The presence of bacteremia and sepsis in percent of critically ill patients and none at all, associated with different expression and faction of Toll-Like-Receptors (TLRs. Read more about this study
- Who is it for?
- Ages 14 years and older
- Conditions the study is for
- Bacteremia and Sepsis, Toll-Like-Receptors (TLRs)
- How many people
- 300 participants
- Where
- 1 siteGreece
- Study dates
- Jul 2009to Aug 2011
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 14 years and older
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Patients who will be nursed in ICU.
Who may be able to join
- presence in Intensive Care Unit
Who cannot join
- Length of stay <24 hours
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Bacteremia in Intensive Care Unit (ICU) and the Role of Toll-Like-Receptors (TLRs)
The presence of bacteremia and sepsis in percent of critically ill patients and none at all, associated with different expression and faction of Toll-Like-Receptors (TLRs.
Read the detailed description
INTRODUCTION Bacteremia is associated with significant morbidity and mortality in critically ill patients and increased the length of hospitalization. Incidence of bacteremia in Intensive Care Units ranges from 8 to 10% and mortality 40%.
Risk factors for the development of bacteremia include the presence of central intravascular catheters, hemodialysis, the use of parenteral nutrition, urine catheters, endotracheal tubes, mechanical ventilation, underlying diseases like cancer, various immunocompromised states, mellitus diabetes, malnutrition, renal and liver failure, transplantations, surgery operations, burns.
The most common microbial pathogens which cause bacteremia are Gram negative pathogens, Pseudomonas species, Staphylococcus aureus, Klebsiella species, Pseudomonas aeruginosa, Candida albicans, Acinetobacter baumanii, Streptococcus pneumoniae.
Toll-like receptors (TLRs) are important for the activation of innate immunity against microbial pathogens. TLRs are transmembrane proteins and are composed of leukine rich extracellular domain, a short intramembrane segment and an intracytoplasmic domain. Intracytoplasmic domain is similar to that of interleukin-1 (IL-1) receptor.
In humans, they have been identified eleven types of recognizing specific pathogen-associated molecular patterns (PAMPs). TLR1 and TLR2 form a heterodimer recognizing bacterial tri-acylated lipopeptides of Gram-positive bacteria. TLR2 and TLR6 form another heterodimer recognizing di-acylated lipopeptides of Gram-positive bacteria. TLR4 is a heterodimer recognizing lipopolysacharedes (LPS)of Gram-negative bacteria while TLR5 is a receptor recognizing flagellae of Gram-negative bacteria. All these aforementioned types of TLRs are expressed on the outer surface of the cell membrane. TLR3, TLR7 TRL8 and TLR9 is a group of receptors expressed on an internal surface of the phagosomes formed in the cytoplasm after the ingestion of the pathogens.TLR3 recognizes viral dsRNA, TLR7 recognizes imidazol-quinollines, TLR8 recognize ssRNA and TLR9 recognize non-methylated bacterial CpG DNA. In addition to bacterial and viral CpG DNA, TLR9 is presumably involved in pathogenesis of autoimmune disorders. TLR10 and TLR11 are still under investigation, although TLR11 seem to recognize uropathogenic bacteria.
We suppose that the presence of bacteremia and sepsis in percent of critically ill patients and none at all, associated with different expression and faction of TLRs Searching of genetic polymorphisms of TLRs which associated with the presence of bacteremia and sepsis in ICU patients, probably will help us to clarify the pathophysiology of sepsis.
Aim
The study is a perspective cohort study which aimed to:
- Search of genetic polymorphisms of TLRs which associated with the presence of bacteremia and sepsis in ICU patients
- Estimate the incidence of bacteraemia
- Search the microbiology of bacteremia
- Correlate the incidence of bacteraemia with clinical parameter, significant for the nursing of critically ill patients in ICU like: Α) the duration of nursing Β) the outcome of nursing
- Correlate the incidence of bacteraemia with probable risk factors like:
- Bronchoscope B) Hemodialysis C) Mechanical ventilation D) Use of central intravascular catheters E) Tracheostomy F) Use of parenteral nutrition G) Use of central intravascular catheters with antiseptic substance
MATERIALS AND METHOD
Settings: The study will be performed in ICU, University Hospital of Larissa (10 beds).
Participants: Participants in the study will be all the patients who will be nursed in ICU for a two years period and they will be studied for all stay in ICU until their transfer to other ward or until their death. Criterion of exclusion of patients from the study will constitute the time of hospitalisation of patients that will be smaller than 24 hours.
Tools: The estimate of incidence of bacteremia but also the investigation of her microbiological explanation and the estimate of her repercussions for the patients it is used the Protocol of Bacteremia This protocol consist data as general elements, elements that concern the bacteremia as the samples, the micro-organisms, the resistance in the antibiotics, the mechanic ventilation, risk factors for growth of bacteremia, the empiric issuing of antibiotics but also the elements of outcomes of patients.
Diagnosis of bacteremia will be based on Centre of Disease Control end Prevention (CDC) criteria.
For the laboratorial detection of polymorphisms of TLR9 will be taken blood samples from the patients in the three first days of their nursing and will be sent in laboratory for analysis. For the laboratorial confirmation of bacteremia will be taken blood cultures or percutaneous or via intravenous catheters, which will be sent for analysis in the laboratory. Each result of blood culture will be also accompanied by the antibiogram according to which will be determined also the therapeutic form of antibiotics from the servant doctors. The reception of blood cultures will be realised in each change of central catheters and in the appearance of fever wave.
The follow-up of patients will become in daily base and essential information will be collected through the cards of nursing and the files of patients with the laboratorial results.
For the estimate of gravity of patients will be used APACHE II Score, Glasgow Scale, and SOFA Scale.
Statistic Analysis:
The statistic analysis of data will be realised with the use of computational parcel of SISS 15.0 for Windows. Data will be compared between bacteremia and no bacteremia groups. The investigation of relation of various potential risk factors with the repercussion of bacteremia, will be realised with the bivariate and multivariate analysis and the statistical method of simple accountant regression (simple Logistic Regression) and multiple accountant regression (multiple Logistic Regression). The odds ratio (OR) and linear coefficient will be calculated and presented with 95% CI. P<0.05 will be considered statistically significant.
- Conditions
- Bacteremia and Sepsis, Toll-Like-Receptors (TLRs)
- Keywords
- bacteremia, sepsis, Toll-Like-Receptors (TLRs)
- Medical subject headings
- Bacteremia, Sepsis
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Jul 2009 (estimated)
- Study startJul 2009
- Primary completionAug 2011 (estimated)
- Study completionAug 2011 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Bacteremia and SepsisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 300 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Thessaly
- Sponsor type
- University, hospital or other
- Investigators
- Maria Chatzi, RN,MSc,ICU, Principal investigator, University Hospital Larisa
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00932243
- Sponsor's protocol ID
- 845UT
- Status last verified
- Jul 2009
- First submitted
- 2 Jul 2009
- Last updated
- 3 Jul 2009
- Results posted
- No
- Data monitoring committee
- No
Publications
Chatzi M, Papanikolaou J, Makris D, Papathanasiou I, Tsezou A, Karvouniaris M, Zakynthinos E. Toll-like receptor 2, 4 and 9 polymorphisms and their association with ICU-acquired infections in Central Greece. J Crit Care. 2018 Oct;47:1-8. doi: 10.1016/j.jcrc.2018.05.012. Epub 2018 May 25.
PubMed 29860039
Study at a glance
From the registry record, last updated by the sponsor on 3 Jul 2009. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Bacteremia in Intensive Care Unit (ICU) and the Role of Toll-Like-Receptors (TLRs)
- ClinicalTrials.gov ID
- NCT00932243
- Acronym / sponsor ID
- 845UT
- Conditions
- Bacteremia and Sepsis, Toll-Like-Receptors (TLRs)
- Keywords
- bacteremia, sepsis, Toll-Like-Receptors (TLRs)
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 300 participants (estimated)
- Lead sponsor
- University of ThessalyUniversity, hospital or other
- Study start
- Jul 2009
- Primary completion
- Aug 2011 (estimated)
- Study completion
- Aug 2011 (estimated)
- First posted
- 3 Jul 2009 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The presence of bacteremia and sepsis in percent of critically ill patients and none at all, associated with different expression and faction of Toll-Like-Receptors (TLRs.
Detailed description
INTRODUCTION Bacteremia is associated with significant morbidity and mortality in critically ill patients and increased the length of hospitalization. Incidence of bacteremia in Intensive Care Units ranges from 8 to 10% and mortality 40%.
Risk factors for the development of bacteremia include the presence of central intravascular catheters, hemodialysis, the use of parenteral nutrition, urine catheters, endotracheal tubes, mechanical ventilation, underlying diseases like cancer, various immunocompromised states, mellitus diabetes, malnutrition, renal and liver failure, transplantations, surgery operations, burns.
The most common microbial pathogens which cause bacteremia are Gram negative pathogens, Pseudomonas species, Staphylococcus aureus, Klebsiella species, Pseudomonas aeruginosa, Candida albicans, Acinetobacter baumanii, Streptococcus pneumoniae.
Toll-like receptors (TLRs) are important for the activation of innate immunity against microbial pathogens. TLRs are transmembrane proteins and are composed of leukine rich extracellular domain, a short intramembrane segment and an intracytoplasmic domain. Intracytoplasmic domain is similar to that of interleukin-1 (IL-1) receptor.
In humans, they have been identified eleven types of recognizing specific pathogen-associated molecular patterns (PAMPs). TLR1 and TLR2 form a heterodimer recognizing bacterial tri-acylated lipopeptides of Gram-positive bacteria. TLR2 and TLR6 form another heterodimer recognizing di-acylated lipopeptides of Gram-positive bacteria. TLR4 is a heterodimer recognizing lipopolysacharedes (LPS)of Gram-negative bacteria while TLR5 is a receptor recognizing flagellae of Gram-negative bacteria. All these aforementioned types of TLRs are expressed on the outer surface of the cell membrane. TLR3, TLR7 TRL8 and TLR9 is a group of receptors expressed on an internal surface of the phagosomes formed in the cytoplasm after the ingestion of the pathogens.TLR3 recognizes viral dsRNA, TLR7 recognizes imidazol-quinollines, TLR8 recognize ssRNA and TLR9 recognize non-methylated bacterial CpG DNA. In addition to bacterial and viral CpG DNA, TLR9 is presumably involved in pathogenesis of autoimmune disorders. TLR10 and TLR11 are still under investigation, although TLR11 seem to recognize uropathogenic bacteria.
We suppose that the presence of bacteremia and sepsis in percent of critically ill patients and none at all, associated with different expression and faction of TLRs Searching of genetic polymorphisms of TLRs which associated with the presence of bacteremia and sepsis in ICU patients, probably will help us to clarify the pathophysiology of sepsis.
Aim
The study is a perspective cohort study which aimed to:
- Search of genetic polymorphisms of TLRs which associated with the presence of bacteremia and sepsis in ICU patients
- Estimate the incidence of bacteraemia
- Search the microbiology of bacteremia
- Correlate the incidence of bacteraemia with clinical parameter, significant for the nursing of critically ill patients in ICU like: Α) the duration of nursing Β) the outcome of nursing
- Correlate the incidence of bacteraemia with probable risk factors like:
- Bronchoscope B) Hemodialysis C) Mechanical ventilation D) Use of central intravascular catheters E) Tracheostomy F) Use of parenteral nutrition G) Use of central intravascular catheters with antiseptic substance
MATERIALS AND METHOD
Settings: The study will be performed in ICU, University Hospital of Larissa (10 beds).
Participants: Participants in the study will be all the patients who will be nursed in ICU for a two years period and they will be studied for all stay in ICU until their transfer to other ward or until their death. Criterion of exclusion of patients from the study will constitute the time of hospitalisation of patients that will be smaller than 24 hours.
Tools: The estimate of incidence of bacteremia but also the investigation of her microbiological explanation and the estimate of her repercussions for the patients it is used the Protocol of Bacteremia This protocol consist data as general elements, elements that concern the bacteremia as the samples, the micro-organisms, the resistance in the antibiotics, the mechanic ventilation, risk factors for growth of bacteremia, the empiric issuing of antibiotics but also the elements of outcomes of patients.
Diagnosis of bacteremia will be based on Centre of Disease Control end Prevention (CDC) criteria.
For the laboratorial detection of polymorphisms of TLR9 will be taken blood samples from the patients in the three first days of their nursing and will be sent in laboratory for analysis. For the laboratorial confirmation of bacteremia will be taken blood cultures or percutaneous or via intravenous catheters, which will be sent for analysis in the laboratory. Each result of blood culture will be also accompanied by the antibiogram according to which will be determined also the therapeutic form of antibiotics from the servant doctors. The reception of blood cultures will be realised in each change of central catheters and in the appearance of fever wave.
The follow-up of patients will become in daily base and essential information will be collected through the cards of nursing and the files of patients with the laboratorial results.
For the estimate of gravity of patients will be used APACHE II Score, Glasgow Scale, and SOFA Scale.
Statistic Analysis:
The statistic analysis of data will be realised with the use of computational parcel of SISS 15.0 for Windows. Data will be compared between bacteremia and no bacteremia groups. The investigation of relation of various potential risk factors with the repercussion of bacteremia, will be realised with the bivariate and multivariate analysis and the statistical method of simple accountant regression (simple Logistic Regression) and multiple accountant regression (multiple Logistic Regression). The odds ratio (OR) and linear coefficient will be calculated and presented with 95% CI. P<0.05 will be considered statistically significant.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 14 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Patients who will be nursed in ICU.
Key inclusion criteria (1 listed)
- presence in Intensive Care Unit
Key exclusion criteria (1 listed)
- Length of stay <24 hours
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Not reported in the source record.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Jul 2009.
- Derived from this study: PubMed 29860039Chatzi M, Papanikolaou J, Makris D, Papathanasiou I, Tsezou A, Karvouniaris M, Zakynthinos E. Toll-like receptor 2, 4 and 9 polymorphisms and their association with ICU-acquired infections in Central Greece. J Crit Care. 2018 Oct;47:1-8. doi: 10.1016/j.jcrc.2018.05.012. Epub 2018 May 25.
Related trials for Bacteremia and Sepsis
RecruitingObservational study
Middle East Study of Infections in Patients With Hematological Malignancies
Hematological Malignancy, Hematopoetic Stem Cell Transplantation
RecruitingPhase 4
Oral Switch in Pediatric Bloodstream Infections
Bloodstream Infection, Bacteremia Sepsis
RecruitingObservational study
Evaluation of Diagnostic Accuracy and Clinical Performance of the UllCORE Bloodstream Infection (BSI) Test
Blood Stream Infection, Blood Stream Infections
Not yet recruitingObservational study
Microbiology Operations & Time Optimization in Sepsis
Sepsis, Bloodstream Infection
RecruitingPhase 2
Combination Cefazolin With Ertapenem for Methicillin-susceptible Staphylococcus Aureus Bacteremia
Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Septicemia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Maria Chatzi, RN,MSc,ICU principal investigator
University Hospital Larisa
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Bacteremia and Sepsis and Toll-Like-Receptors (TLRs), run by University of Thessaly at 1 site in Greece.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 3 Jul 2009. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Greece. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00932243, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Jul 2009; AzTrials last refreshed its copy on 30 Oct 2026.